Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Greybadger ? What do you mean pps? companies house is still showing as active for dr Andrew James Bowen
Major Highlights
· Early in 2021, we aligned and focused resources to accelerate the development of IB Zero G™, the Artificial Intelligence (AI) model for generating simulated "with contrast" images using non-contrast (0% gadolinium) images as input. The effort included the labelling of many datasets necessary to be used to perfect the AI model. Sufficient progress was made throughout the year and a 510(k) application to the US FDA is in now in preparation with submission for approval anticipated in May '22.
· Last April 2021, we announced the sponsorship of a Phase I clinical trial. The trial follows a successful pre-clinical study that showed that the potential therapeutic compound Gallium Maltolate (GaM) shrunk glioblastoma (GBM) cells in animal models. In June 2021, the FDA approved the investigational new drug (IND) application for GaM and the treatment of the most aggressive form of brain cancer, GBM, and the first-in-human trial of an oral form of GaM has now commenced in the USA.
· In April 2021, a $3 million grant was awarded in collaboration with Professor Kathleen Schmainda, PhD, from the Medical College of Wisconsin (MCW). The National Institutes of Health (NIH)-funded grant will be used to validate and translate an AI model that can detect infiltrating tumour cells before they are visible on standard imaging. This would represent the ultimate in early detection.
· In June 2021, we were awarded a US patent for the AI technology contained in IB Zero G™. This 0% contrast media dose approach has the potential of offering remarkable benefits which include a more comfortable patient experience, more productive radiology departments, and reduced risks associated from the long-term, albeit uncertain, side effects of repeated GBCA use.
· In September 2021, we received a European patent for IB's "dual-echo" technology. Previously patented in the US, this technology combines MR scanner data acquisition and post-processing to generate two unique sets of data that currently require two independent MR exams. In addition, the technology eliminates the need for the commonly accepted "pre-load" dose of gadolinium-based contrast agent and minimizes other imaging artefacts inherent with this type of imaging. The advancement of this technology is being done in collaboration with the Barrow Neurological Institute under a funded NIH grant. An additional aim of the grant is to harmonize this approach across all major scanner platforms.
· In November 2021, MD Anderson Cancer Centre (University of Texas, Houston) adopted IB Clinic - container edition. MD Anderson is consistently ranked as the #1 cancer centre in the USA and is a recognized leader in using cutting edge technologies in an attempt to improve patient outcomes. This installation again underscores the significance of the automated and quantitative capability of IB Clinic - container edition.
Lots to look forward to!
GLA
IB Neuro's advanced MR imaging has been shown repeatedly to distinguish tumor from treatment using MRI data alone. Automated & quantitative, enables direct longitudinal comparison too.
PET superior to MRI for meningioma treatment planning via
@AuntMinnie
https://twitter.com/IQAI_IB/status/1518590548860452864
We should get confirmation of $2m receive, by end of next week. As 30 days are up
“The funds due under the Subscriptions are contracted to be received within 30 days, at which point an update announcement will be made”.
Richard Shearer, Tintra CEO, said, "This investment from the family of a renowned New York based private equity professional is perhaps the strongest validation we have yet received of the substance and future of our model and execution plans.
The board of directors of Tintra (the "Board") is pleased to confirm that further to the announcement of 7 March 2022 (the "Announcement"), that it has received the subscription agreements under the current funding round for a further US$2,000,000 (the "Subscriptions"). As set out in the Announcement, these are the Family of the private equity professional based in New York City, who has already agreed to invest $250,000, and consists of two investments of $1,000,000 each by separate limited liability companies. This brings the total investment by the Family or related entities to US$2,250,000, not the $2,275,000 provided in the Announcement. The investment has no conditionality.
https://virtualtrials.org/newsarticle.cfm?item=7231…
"This exciting clinical trial has recently opened for patients with relapsed or refractory Glioblastomas. The
@AlMusella
Foundation has funded early work on this drug, and we had a webinar about it. See..."
https://virtualtrials.org/video2021.cfm?video=202105
Nice recognition for Kathleen Schmainda PhD,
@aimbe
Fellow, and her involvement in the Phase I Clinical Trial by The American Institute for Medical and Biological Engineering.
With over a decade of experience in quantitative brain tumor imaging analysis, including analysis for several national multi-center trials, Imaging Biometrics will provide image analysis solutions for evaluating the response to GaM. "We are working with an excellent team of scientists and clinicians, and everyone is eager to move this study forward," says Michael Schmainda , CEO of Imaging Biometrics.
The trial, being conducted at Froedtert & the Medical College of Wisconsin, is currently accepting participants and has an anticipated completion date of December 2025.
Results from pre-clinical research show iron-like compound holds promise for treating patients with glioblastoma, an aggressive brain cancer
MILWAUKEE , April 8, 2022 /PRNewswire/ -- A novel therapy studied at the Medical College of Wisconsin (MCW) Cancer Center has led to a clinical trial for the treatment of glioblastoma, a rare and aggressive form of brain cancer, yet the most common primary brain tumor in adults.
Despite decades of research globally, only incremental gains have been made to extend or enhance quality of life for patients with glioblastoma. Treatment options are limited and typically include a combination of surgery, radiation therapy, and chemotherapy. Now, a new clinical study open at Froedtert & the Medical College of Wisconsin will evaluate an alternative treatment that is administered orally.
The treatment evolved from years of research led by Christopher Chitambar, MD, and his lab to study iron-dependent processes in cancer biology and the mechanisms by which gallium compounds target iron metabolism and block malignant cell growth. In preclinical studies, Drs. Chitambar and Kathleen Schmainda, PhD, discovered that gallium maltolate (GaM) significantly slowed the growth, and reduced the size, of glioblastoma.
GaM, originally developed by Harvard and Stanford educated scientist Lawrence R. Bernstein, PhD, is an orally available form of the metal gallium, which, in the body, shares many chemical properties with the highly oxidized form of iron, called Fe(III). Numerous studies examining the relationship between iron and cancer show that increased levels of iron in the body can be associated with increased cancer risk and severity, because cancer cells depend on iron to multiply and spread. Because of gallium's similarity to Fe(III), it enters cancer cells instead of iron, preventing their multiplication.
"The discovery that GaM has anticancer activity against glioblastoma in pre-clinical studies is extremely exciting; it opens the door for developing it as a drug for treatment of glioblastoma in patients," says Christopher Chitambar, MD, Emeritus Professor of Medicine and Biophysics, Division of Hematology and Oncology at MCW. "The anticancer mechanism of GaM applies to other solid tumors as well," he adds.
Jennifer Connelly, MD, Associate Professor of Neurology at MCW, is Principal Investigator (PI) of the clinical trial with Dr. Chitambar serving as co-PI and Chair. Both are long-standing collaborators with Kathleen Schmainda, PhD, a co-founder of Imaging Biometrics, LLC, and a recognized leader in brain tumor imaging. Dr. Bernstein is participating as a co-investigator.
The trial is being sponsored by Imaging Biometrics with supporting grants from the Musella Brain Tumor Foundation and the MCW Cancer Center. Based in Elm Grove, WI, Imaging Biometrics is a wholly owned subsidiary of IQ-AI Ltd.
With over a decade of experience in quantitative brain tumor imaging analysis, including analysis for sever
Experimental: Dose-escalation Phase (1,500 mg)
This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
Experimental: Dose-expansion Phase
A minimum of six participants will be enrolled in the dose expansion phase for a total of 12 subjects at the recommended phase 2 dose.
Primary Outcome Measures :
1 Maximum-tolerated dose. [ Time Frame: Each 28-day cohort ]This will be determined from the incidence of dose limiting toxicities at each dosage.
Secondary Outcome Measures :
1 Progression-free survival [ Time Frame: 6 months ]This measure is the number of months participants remain free from evidence of disease. Imaging will be done every eight weeks and reported at six months.
2 Overall survival [ Time Frame: 6 months ]Overall survival is determined as the average number of months subjects survived following enrollment.
3 Dose-limiting toxicity [ Time Frame: 28 days for each cohort ]Number of participants experiencing a dose limiting toxicity.
Experimental: Dose-escalation Phase (500 mg)
This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
Experimental: Dose-escalation Phase (1,000 mg)
This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
#IQAI $IQAIF
IB Neuro accurately measures cerebral blood volume (CBV) from MRI data (perfusion MRIs) and provides information to help your doctor make a more accurate diagnosis of your tumor and provides more accurate and personalized treatment monitoring
https://twitter.com/kaneinthename/status/1507703944415522825
Shout out to
@VslsKatsaros
for showing the utility of IB’s quantitative FTB maps for accurately monitoring treatment response. This talk was given at the SBMT (Society of Brain Mapping and Therapeutics) that took place in Los Angeles on Sunday.
Delta T1 maps (patent pending) help alleviate "tired eyes" and prevent burnout experienced by radiologists. They can also be used to assess new biomarkers: https://mdpi.com/1542604
Quantitative Delta T1 maps take the guesswork out of pre- and post-contrast reads.
@MDPIOpenAccess
https://twitter.com/IQAI_IB/status/1503763473901277189
An exciting journey begins...
@gbmfoundation
@NBTStweets
@theABTA
@CancerSupportHQ
@CancerHopeNet
@TBCGBrainCancer
@curemotive
@IvyFoundation
@AlMusella
https://twitter.com/IQAI_IB/status/1502362662105194497
Panel of International Experts Deem MR DSC Perfusion as Most Clinically Validated
MILWAUKEE, WI / ACCESSWIRE / March 7, 2022 / Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB:IQAIF) (LSE:IQAI), is pleased to announce the publication of a review authored by International scientists about the use of advanced MRI techniques in Europe.
The paper, published in Frontiers in Oncology, was written by a team of clinicians, engineers, and physicists working on behalf of the European Cooperation in Science and Technology (COST) Glioma MR Imaging 2.0 (GLiMR) Initiative. It consisted of a comprehensive review of advanced MRI techniques used in Europe for monitoring treatment response in high-grade brain tumors. The authors of the study concluded that dynamic susceptibility contrast (DSC) MRI is the most proven of all advanced methods. IB's software modules, IB Neuro™ and IB DCE™, provided solutions for analysis of this data, with examples from each included in the paper.
The study acknowledged the limitations and challenges presented with conventional MRI and specifically noted the quantitative technology contained in IB Neuro termed "standardization." This exclusive technology is built into IB Neuro and automatically generates standardized relative cerebral blood volume (sRCBV) maps. And, as the paper cites, IB Neuro's sRCBV has demonstrated greater consistency and improved repeatability over the inherently variable and manual "tissue normalization" approaches.
"Standardization is significant because it allows for direct comparison between scans independent of MR scanner platform, field strength, or patient," said Michael Schmainda, CEO of IB. "This paper nicely summarizes the advancements made over the years in advanced MRI techniques, and we are pleased that the sRCBV technology available in IB Neuro was highlighted."
https://twitter.com/AccesswireNews/status/1500844205819760641
More to come.
The Subscription is made by a private equity professional based in New York City. This investment is part of a larger investment related to his family's Family Office which is anticipated to subscribe to a further US$2.025m on the same terms, for which the documentation is currently in process (the "Additional Subscriptions").
TINTRA PLC
("Tintra", the "Group" or the "Company")
Further Strategic Investment Under Funding Round
The board of directors of Tintra (the "Board") is pleased to announce that further to the announcement of 26 November 2021, that it has finalised a further subscription under the current funding round, raising a further US$250,000 (the "Subscription").
The Subscription is for 37,128 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares"), priced at 504 pence per Ordinary Share, at an exchange rate of £1.00:$1.336 (the "Subscription Price").
For each new Ordinary Share purchased under the Subscription, the investor will receive two warrants to subscribe for new Ordinary Shares at an exercise price of 50 pence per Ordinary Share for a period of five years, conditional on either the market capitalisation of the Company exceeding US$250m for a period of three consecutive trading days or a future funding round being concluded with a post-money valuation of US$250m or greater (the "Warrants").
The Subscription is made by a private equity professional based in New York City. This investment is part of a larger investment related to his family's Family Office which is anticipated to subscribe to a further US$2.025m on the same terms, for which the documentation is currently in process (the "Additional Subscriptions").
The funds to be received will be used for the continuing development of the Company's artificial intelligence platform and regulatory licensing build alongside general working capital purposes.
The Subscription and Additional Subscription are all expected to complete and funds received during March 2022, at which point an update announcement will be made.
Richard Shearer, Tintra CEO, said, "I am extremely pleased to have on board this new partner and investor. One that shares our artificial intelligence driven vision of revolutionising how emerging markets directly benefit from financial inclusion. The family have deep private equity experience and those insights have already started to assist in our thinking. I know this is something that I will draw on, and will add value for the board and shareholders, over the coming months and years as we build out our game changing model."